Incannex Healthcare Inc. (IXHL) stock: key figures, P/E, revenue and dividend

Health Care · ISIN US45333F2083

Price
2.58 USD
Market cap
32.37 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-28.65 %
Return on assets (ROA)
-26.45 %

Incannex Healthcare Inc. financials

Fiscal year20252026
Revenue86,000.00 USD0.00 USD
Operating income-23.79 m USD-23.03 m USD
EBIT-46.64 m USD–
Net income-46.89 m USD-19.30 m USD
Diluted EPS – continuing operations-1.35 USD-1.66 USD

Full history since 2006, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Incannex Healthcare Inc.

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.